The invention provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.

The present invention relates to compounds of formula I: in which A.sup.1-A.sup.7 and R.sup.1 to R.sup.5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A.sup.1 to A.sup.3 is N or at least one of A.sup.4 is CR.sup.12 or A.sup.5 is CR.sup.13 in which R.sup.12/R.sup.13 is halogen.

The present invention relates to compounds of formula I: in which A.sup.1-A.sup.7 and R.sup.1 to R.sup.5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A.sup.1 to A.sup.3 is N or at least one of A.sup.4 is CR.sup.12 or A.sup.5 is CR.sup.13 in which R.sup.12/R.sup.13 is halogen.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

The present invention relates to compounds of formula I:

##STR00001## in which A.sup.1-A.sup.7 and R.sup.1 to R.sup.5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A.sup.1 to A.sup.3 is N or at least one of A.sup.4 is CR.sup.12 or A.sup.5 is CR.sup.13 in which R.sup.12/R.sup.13 is halogen.

The present invention relates to compounds of formula I:

##STR00001## in which A.sup.1-A.sup.7 and R.sup.1 to R.sup.5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A.sup.1 to A.sup.3 is N or at least one of A.sup.4 is CR.sup.12 or A.sup.5 is CR.sup.13 in which R.sup.12/R.sup.13 is halogen.